In this study we describe the design, synthesis, and antibacterial activity of novel pleuromutilin analogs. A series of new compounds containing piperazine and alkylamino or arylamino groups was synthesized. The new compounds were characterized via 1 H-NMR, 13 C-NMR, Fourier transform (FT)-IR and MS, and were further evaluated for their in vitro activity against seven Gram-positive, and one Gram-negative, pathogens. Antibacterial data revealed that all compounds exhibited moderate to good antibacterial activities against sensitive Gram-positive pathogens. Specifically, 9d displayed the best activity: its activity to Staphylococcus aureus (ATCC25923) is 0.125 µg/mL, which is equal to the control compound tiamulin. The antibacterial activities of 9d to Streptococcus suis (minimum inhibitory concentration (MIC) of 2 µg/mL), Streptococcus agalactiae (MIC of 0.5 µg/mL), and Streptococcus dysgalactiae (MIC of 0.5 µg/mL) were also excellent compared with the control drug erythromycin (MIC of >128 µg/mL). The binding modes of these compounds with active sites were calculated using the programs of Molecular Operating Environment (MOE) and Pymol.Key words pleuromutilin; antibacterial activity; design; synthesis; Gram positive Although countless lives of people have been saved since the discovery of antibiotics, the problem with bacterial resistance to many antibiotics, especially cross resistance, has been increasing. Therefore, we need to identify and develop new antibacterial agents with novel mechanisms of action against bacterial strains. 1) Thus far, the use of natural products or semisynthetic derivatives of natural products has been the most successful method of developing new antibiotics.Pleuromutilin (1) ( Fig. 1) was first isolated in 1951 from basidiomycetes Pleurotus and P. passeckerianus, and it exhibits modest in vitro activity against Gram-positive pathogens and mycoplasmas [2][3][4] and weaker in vivo activity. Pleuromutilin has an unusual 5-6-8 tricyclic diterpene structure. This structure was reported by Birch et al. in the 1960 s and was then confirmed via X-ray crystal diffraction technology. 5) Further studies have shown that this class of antibiotics interferes with bacterial protein synthesis via a specific interaction with Domain V of the 23S ribosomal RNA (rRNA) of the 50S bacterial ribosome subunit, Cross-resistance with other antimicrobial classes is uncommon.6,7) Specifically, these compounds could bind to the peptidyl transferase center (PTC) of the ribosomal 50S subunit with its tricyclic mutilin core positioned in a tight pocket at the A-tRNA binding site, which subsequently prevents the correct positioning of the CCA ends of tRNAs for peptide transfer.7-9) All of the aforementioned interactions involve prokaryotic ribosomes and not eukaryotic proteins and mammalian ribosomes. 4) Based on the structure-activity relationship (SAR) studies, we know that the 5-6-8 tricyclic core is essential for bioactivity, and the carbonyl of C3 and the hydroxyl of C11 are the key groups of antibacterial acti...